



## (51) International Patent Classification:

C07K 7/08 (2006.01) A61K 39/215 (2006.01)  
C07K 14/165 (2006.01) A61P 31/14 (2006.01)  
G01N 33/53 (2006.01)

## (21) International Application Number:

PCT/SG2021/050178

## (22) International Filing Date:

30 March 2021 (30.03.2021)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

10202002981P 30 March 2020 (30.03.2020) SG  
10202004276P 08 May 2020 (08.05.2020) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way,  
#20-10 Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: **AMRUN, Siti Naqiah**; c/o Singapore Immunology Network, 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG). **POH, Chek-Meng**; c/o Singapore Immunology Network, 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG). **CARISSIMO, Guillaume**; c/o Singapore Immunology Network, 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG). **LEE, Cheryl Yi-Pin**; c/o Singapore Immunology Network, 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG). **NG, Lisa Fong Poh**; c/o Singapore Immunology Network, 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG). **RENIA, Laurent Claude**; c/o Singapore Immunology Network, 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG). **CHEE, Rhonda Sin-Ling**; c/o Singapore Immunology Network, 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG). **YEO, Nicholas Kim-Wah**; c/o Singapore Immunology Network, 8A Biomedical Grove, #04-06 Immunos, Singapore 138648 (SG).

## (54) Title: EPITOPES OF SARS-COV-2




FIG. 16

(57) **Abstract:** There is provided an isolated immunogenic polypeptide or epitope comprising at least 12 contiguous amino acids of one or more SARS-CoV-2 protein selected from the group consisting of a spike (S) protein, an envelope (E) protein, a membrane (M) protein, and a nucleocapsid (N) protein. Also disclosed are a pharmaceutical composition thereof, a composition thereof, and an antigen binding molecule capable of specifically binding to the polypeptide or epitope thereof. Also disclosed are a method of detecting the presence of SARS-CoV-2 virus, a method of predicting the severity of a SARS-CoV-2 infection, a kit thereof, a method of treating or preventing SARS-CoV-2 and uses thereof.

[Continued on next page]

(74) **Agent: DONALDSON & BURKINSHAW LLP**; 24 Raffles Place, #15-00 Clifford Centre, Singapore 048621 (SG).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *of inventorship (Rule 4.17(iv))*

**Published:**

— *with international search report (Art. 21(3))*  
 — *with sequence listing part of description (Rule 5.2(a))*  
 — *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*